ABBV Stock Analysis — AbbVie
Sector: Healthcare
AI Verdict
AbbVie trades at 15.4x next year's earnings with a 707.9% EPS growth forecast—cheap for the growth on offer if its drug pipeline and patent moat hold, but the overbought RSI warns of near-term volatility.
Competitive Moat
AbbVie defends its cash flows with a portfolio of blockbuster drugs, most notably immunology therapies like Humira and Skyrizi, supported by a deep pipeline and patent protections. Its scale and established relationships with payers and providers create barriers for new entrants in specialty pharmaceuticals.
Summary
A 707.9% forward EPS growth forecast and a drop to 15.4x forward P/E make AbbVie's valuation swing dramatic after a year of patent cliffs.
Where It Stands
AbbVie has returned 33.16% in the past year, trades at 15.4x forward earnings versus the healthcare sector median of 22x, and its RSI of 73.7 signals overbought territory.
Key Metrics
- RSI: 73.7 — Overbought
- Trailing P/E: 124.7x
- Forward P/E: 15.4x
- PEG Ratio: 0.18
- Earnings Growth: +7.1%
- Revenue Growth: +0.1%
- Market Cap: $447.9B
- Dividend Yield: 0.03%
- 1-Year Return: 33.16%
- 52-Week High: $261.63
- 52-Week Low: $184.63
Analyst Consensus
31 Buy · 8 Hold · 0 Sell (39 analysts) · Target $274.50
Bull Case
With forward EPS expected to jump 707.9% and the stock trading at just 15.4x those earnings, you're paying a bargain multiple for a massive earnings rebound if the pipeline delivers.
Bear Case
The RSI at 73.7 flags overbought risk, so a pullback to a neutral RSI could mean a 10–15% drop even if the earnings story holds.
Catalyst to Watch
Watch for FDA approvals and major clinical trial readouts—positive data could lock in the expected earnings surge, while setbacks would undermine the low forward multiple.